Under FDA regulations, any individual or entity can petition the agency to take (or refrain from taking) a specific administrative action. In the context of pharmaceuticals, these are often used to raise concerns about the safety or bioequivalence of a pending generic drug application (ANDA). 2. The "Sham" Petition Concern
Prevents the FDA from delaying the approval of a generic drug unless a delay is necessary to protect public health. 06C1C8EE-6564-46FE-9989-DBF4FBF086FE_1531776 - ...
In the complex world of pharmaceutical regulation, the serves as a vital public safety valve. However, as explored in the paper associated with your identifier, this mechanism has also been scrutinized as a potential tool for "gaming" the system to delay the market entry of lower-priced generic drugs. 1. What is a Citizen Petition? Under FDA regulations, any individual or entity can
Feature: The Strategy of Delay — Understanding FDA Citizen Petitions The "Sham" Petition Concern Prevents the FDA from
The core issue discussed in the SSRN study (ID 1531776) is whether brand-name manufacturers use these filings strategically.
Sets strict timelines for FDA responses (currently 150 days).